Cutaneous manifestation of systemic lupus erythematosus [SLE], correlation with specific organ involvement, specific auto Antibodies and disease activity and outcome.

DR; Fathia Ehmouda zaid1, DR. Naziha Abudsalam2

Department of Rheumatology, Benghazi University, Libya

Corresponding author: Fathia Ehmouda Zaid, Assistant Professor, Faculty of Medicine, Benghazi University, Libya, Tel: 0193424950; E-mail: fatehmoda@yahoo.com

Abstract

Cutaneous lesions are important as a diagnostic aid as these account for 4 out of 11 revised American Rheumatism Association criteria for disease classification

Result;

Cutaneous manifestation of systemic lupus erythematosus (74.4%) and most patients had Butterfly rash (48.8%), Photosensitivity (41.9%) , acute cutaneous lupus erythematosus (SCLE) (32.6%), Discoid lupus (20.9%), Nail lesions (16.3%) , Alopecia (23.3%), oral-nasal ulcer (37.2%), purpuric rash (23.3%) , Raynaud phenomenon (16.3%), Livedo reticularis (9.3%), Telangiectasias (4.6%), and Urticarial lesion (2.3%). Lupus profundus (2.3%), Cutaneous manifestation of systemic lupus erythematosus are association with disease activity (97.7%) ,Cutaneous manifestation of systemic lupus erythematosus are association with musculoskeletal (MSK) (62.8%), Renal disease (27.9%), Hematologic disease (23.3%), Serositis (9.3%), Neurologic disease (14%),and cardiac disease (9.3%), Cutaneous manifestation of systemic lupus erythematosus are association with positive ANA (90.3%) and negative ANA (9.3%), positive ds DNA (74.4%), , positive Anti-Ro (69.8%), positive Anti-La (9.3%) , positive Anti-SM (48.8%),and positive Anti-RNP (39.5%).

outcome of cutaneous manifestation of systemic lupus are skin atrophy and scarring (27.9%), pigmentation (25.6%) and alopecia (23.3%)

Conclusion

The cutaneous lesions can provide valuable diagnosis of systemic lupus erythematosus
The most cutaneous manifestations are epidermal lesion then mucous-cutaneous lesion then vascular lesion, are associated with disease activity, and associated with high titer auto antibodies

Key word  cutaneous manifestations- systemic lupus erythematosus- disease activity
**Introduction:**
Cutaneous lesions are important as a diagnostic aid as these account for 4 out of 11 revised American Rheumatism Association criteria for disease classification\(^1,2\)
The diagnosis of the cutaneous manifestations of systemic lupus erythematosus (SLE) is based on clinical, histopathology, and immunohistology, in addition, serum autoantibodies are considered immunologic markers for distinct clinical types of the illness.
The cutaneous lupus erythematosus disease area and severity index (CLASI) is used as a clinical tool that standardizes the way disease activity is described and provides guidelines for identifying a clinical change, this clinical tool quantifies disease activity and damage in cutaneous lupus erythematosus\(^3\)
The activity score is based on the erythema, scale, mucous membrane lesions, and non-scarring alopecia.

**Cutaneous manifestations of Systemic Lupus Erythematosus (SLE).**

A - Epidermal lesion
1. Butter fly rash
2. Discoid Lupus Erythematosus (DLE)
3. Photosensitivity
4. Subacute Cutaneous Lupus Erythematosus
5. Alopecia
6. Lupus panniculitis/lupus profundus
7. Bullous lesion
8. Nail lesion
9. Lichenoid DLE (LE/lichen planus overlap)
10. Neonatal lupus

B - Mucous membrane
1. Gingivitis
2. Oral ulcers
3. Nasal ulcer

C - Vascular lesion
1. Raynaud’s phenomenon
2. Periungual telangiectasia’s
3. Livedo reticularis
4. Urticarial vasculitis
5. Purpura vasculitis
6. Telangiectasia’s, Jane way lesions, Osler’s nodes, Chilblain lupus
7. Atrophie blanche lesions

The main purpose of this study is estimation cutaneous manifestation of systemic lupus erythematosus, correlation with disease activity, immunology test, specific organ involvement and outcome in Libyan patients.
Patient and methods
This study was carried out at the Rheumatology department, Benghazi University, 7th October -hospital, Libya, Follow up study (43) patients diagnosed as systemic lupus erythematosus (SLE) according to the American College of Rheumatology (ACR), in between June 2008 and December 2010, these patients were studied clinically for the presence of cutaneous manifestation by use The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is clinical tool that standardizes the way disease activity is described and provides guidelines for identifying a clinical change, this clinical tool quantifies disease activity and damage in cutaneous lupus erythematosus. The activity score is based on the erythema, scale, mucous membrane lesions, and non-scarring alopecia[^3], and use immunology test ANA positivity was more than 1:160, anti-DNA Serum compliment levels (C3, C4), anti-ENA, and use SLEDAI.
Result;

Forty-three patients diagnosed with systemic lupus erythematosus were included in the study. Patients’ clinical characteristics are shown below (Table 1). The age of the study patients ranged from (18-55 years), \( M= (17\pm55Y) \), 42 (97.7%) were female, 39 (90.7%) were white and 4 (9.3%) were black. Prevalence of Cutaneous manifestation of systemic lupus erythematosus were 32 (74.4%). The most common Cutaneous manifestations of systemic lupus erythematosus in the study were as follow: Butterfly rash 21 (48.8%), then Photosensitivity 18 (41.9%), then Sub-acute cutaneous lupus erythematosus (SCLE) 14 (32.6%), then Discoid lupus 9 (20.9%) out of which preceding development of SLE 2 (4.6%) and 7 (16.3%) meet criteria for diagnoses of SLE. then Nail lesions 7 (16.3%) then involvement oral-nasal ulcer 16 (37.2%), then purpuric rash 10 (23.3%), then Raynaud phenomenon 7 (16.3%) and Livedo reticularis 4 (9.3%). Most Cutaneous manifestation of systemic lupus erythematosus are association with active disease 42 (97.7%).

Most Cutaneous manifestation of systemic lupus erythematosus are association with musculoskeletal (MSK) 27 (62.8%), then Renal disease 12 (27.9%), then Hematologic (14%), then Serositis 4 (9.3%), and cardiac disease 10 (23.3%) then Neurologic disease 6 disease 4 (9.3%). Laboratory findings are summarized in Table 2. Most Cutaneous manifestation of systemic lupus erythematosus are association with positive ANA (90.3%) and negative ANA (9.3%), positive ds DNA (74.4%), positive Anti-Ro (69.8%), positive Anti-La (9.3%), positive Anti-SM (48.8%), and positive Anti-RNP (39.5%).

We demonstrated (Figure 1) Clinical course of cutaneous manifestations are progression into skin atrophy and scarring 12 (27.9%) then pigmentation 11(25.6%) and alopecia 10 (23.3%).
Discussion

The skin and mucous membranes are involved at some point in over 80% of patients with systemic lupus erythematosus (SLE) \[^{4}\].

Cutaneous manifestation of systemic lupus erythematosus is characterized by an epidermal lesion. Vascular lesion and Mucous membrane lesion \[^{5}\].

Cutaneous illness often precedes the systemic involvement, giving the opportunity to the dermatologist to recognize the disease process much before the systemic complaints are expressed. This will allow the institution of appropriate management and prevent the subsequent morbidity and mortality \[^{6}\].

Skin lesions in patients with SLE are important disease manifestations which can serve as diagnostic aid as well as prognostic information, in the present study prevalence of cutaneous involvement was (74.4%), majority initial presentation and (4.6%) preceding development of SLE. Similarly in neuromas studies \[^{7,8,9}\] Butterly rash and Photosensitivity were most common lesion similarly in Arabian studies \[^{10,11,12}\] than European studies \[^{13,14,15}\], this variation may be attributable to different climatic conditions.

Nail lesions, included onycholysis, pitting nail, dystrophic nail are common seen in our study, which contributed to chronicity of disease. Other lesion like splinter hemorrhages and peri ungual erythema was not seen in our study.

The oral and nasal ulcers of systemic lupus Different figures of the incidence Seen by conducted studies \[^{16,17}\].

Raynaud phenomenon and purpuric rash were common cutaneous vasculitis. Which was much less than from European studies \[^{13,14,15}\], due to different climate condition.

Most cutaneous manifestation of systemic lupus erythematosus are association with Musculoskeletal (MSK).

Most Cutaneous manifestation of systemic lupus erythematosus are association with positive ANA and Anti-ds DNA antibodies which are specific for the diagnosis \[^{18}\], and association with high titer auto antibodies and positive anti-Ro, anti-La, and anti-RNP antibodies more more likely to have cutaneous involvement.

Skin lesions in these patients produce considerable morbidity by producing alopecia, scarring lesions, disfigurement, hyper pigmentation, etc. \[^{19}\].

Hyper pigmentation was noted 25.6% of our study which higher than reported in other European studies \[^{14,15,19}\]. This difference could be due to excessive exposure to sunlight in our country.
Conclusion
The cutaneous lesions can provide valuable diagnosis of systemic lupus erythematosus
the most cutaneous manifestations are epidermal lesion include butterfly rash, photosensitivity, and then mucous-cutaneous lesion then vascular lesion, the most cutaneous manifestations are associated with disease activity, and associated with high titer auto antibodies
Clinical course of cutaneous manifestations are variable from mild skin lesion in to sever skin lesion with dermal damage like hyper pigmentation, skin atrophy scarring and alopecia.

Acknowledgment
Iam grateful to all patients who participated and help in accomplishing this work and would like to thank to my family support me

Competing Interest
They have no competing interest's nan-financial competing interests, and answers for all questions are None, did not have any financial competing interests
There are competing interests as personal, academic and intellectual
References


10- Hanan Fathi. Cutaneous manifestations of systemic lupus erythematosus. A retrospective study from Egypt in Gulf Journal of Dermatology and Venereology Volume 17, No.1, April 2010


<table>
<thead>
<tr>
<th><strong>Table [1] Clinical Characteristics of patients in Systemic Lupus Erythematosus [SLE]</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
</tr>
</tbody>
</table>
| **Sex** | female 42 [97.7%]  
            Male 1 (3.2%) |
| **Racial** | White 39 (90.7%)  
                  Black 4 (9.3%) |
<p>| <strong>Cutaneous Manifestation Of Systemic Lupus Erythematosus</strong> | 32 [74.4%] |
| <strong>Disease Activity</strong> | 42 [97.7%] |
| <strong>Musculoskeletal (MSK)</strong> | 27 [62.8%] |
| <strong>Renal Disease</strong> | 12 [27.9%] |
| <strong>Hematologic Disease</strong> | 10 [23.3%] |
| <strong>Serositis</strong> | 4 [9.3%] |
| <strong>Neurologic Disease</strong> | 6 [14%] |
| <strong>Cardiac Disease</strong> | 4[9.3%] |</p>
<table>
<thead>
<tr>
<th>Table (2) Cutaneous manifestation of systemic lupus erythematosus</th>
</tr>
</thead>
<tbody>
<tr>
<td>I) Epidermal lesion</td>
</tr>
<tr>
<td>Butter fly rash</td>
</tr>
<tr>
<td>Discoid lupus</td>
</tr>
<tr>
<td>Photosensitivity</td>
</tr>
<tr>
<td>SCLE Sub-Acute Cutaneous Lupus Erythematosis</td>
</tr>
<tr>
<td>Alopecia</td>
</tr>
<tr>
<td>Lupus profundus</td>
</tr>
<tr>
<td>Nail lesion</td>
</tr>
<tr>
<td>II) Mucosal ulcer</td>
</tr>
<tr>
<td>III) Vascular lesion</td>
</tr>
<tr>
<td>Raynaud’s phenomenon</td>
</tr>
<tr>
<td>Livedo reticularis</td>
</tr>
<tr>
<td>Telangiectasias</td>
</tr>
<tr>
<td>Purpuric rash</td>
</tr>
<tr>
<td>Urticarial vasculitis</td>
</tr>
</tbody>
</table>
Table (3) Correlation between Auto antibodies and cutaneous manifestation of SLE

<table>
<thead>
<tr>
<th>Positive Auto antibodies</th>
<th>%</th>
<th>Cutaneous manifestation</th>
<th>Non Cutaneous manifestation</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANA</td>
<td>39/43 (90.7%)</td>
<td>28/43 (65.1%)</td>
<td>11/43 (25.6%)</td>
</tr>
<tr>
<td>DSDNA</td>
<td>32/43 (74.4%)</td>
<td>26/43 (60.4%)</td>
<td>6/43 (14%)</td>
</tr>
<tr>
<td>RNP</td>
<td>17/43 (39.5%)</td>
<td>13/43 (30.2%)</td>
<td>4/43 (9.3%)</td>
</tr>
<tr>
<td>Anti-SM</td>
<td>21/43 (48.8%)</td>
<td>16/43 (37.2%)</td>
<td>5/43 (11.6%)</td>
</tr>
<tr>
<td>Anti -RO</td>
<td>30/43 (69.8%)</td>
<td>22/43 (51.2%)</td>
<td>8/43 (18.6%)</td>
</tr>
<tr>
<td>Anti- LA</td>
<td>4/43 (9.3%)</td>
<td>3/43 (6.9%)</td>
<td>1/43 (2.3%)</td>
</tr>
</tbody>
</table>
figure (1) Outcome of cutaneous manifestation of systemic lupus erythematosus

- Alopecia: 28%
- Pigmentation: 23.3%
- Skin atrophy and scarring: 25.6%